Trial on Safety & Performance of TAXUS Element vs. XIENCE Prime Stent in Treatment of Coronary Lesion in Diabetics

NACompletedINTERVENTIONAL
Enrollment

1,830

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2016

Conditions
Type 2 DiabetesCoronary Heart Disease
Interventions
DEVICE

TAXUS Element™ Paclitaxel-Eluting Stent System

Texus Element is the next generation Boston Scientific paclitexel-eluting coronary sten and received DCGI approval on April 13th, 2010.

DEVICE

Xience PRIME Everolimus-Eluting Stent System

The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA, as Xience Prime.

Trial Locations (1)

110025

Fortis Escorts Heart Institute, New Delhi

Sponsors
All Listed Sponsors
collaborator

Boston Scientific Corporation

INDUSTRY

collaborator

Max Neeman Medical International Ltd.

UNKNOWN

lead

Fortis Escorts Heart Institute

OTHER